Statistiche di base
| LEI | 875500IY38EWGFPSEV72 |
| CIK | 1818838 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Adagene Inc. - Depositary Receipt (Common Stock)
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| August 12, 2025 |
Exhibit 99.1 Adagene Reports Six Months 2025 Financial Results and Provides Corporate Updates Muzastotug (ADG126) Phase 1b/2 in MSS CRC shows 19.4-month median OS (mOS) in 10 mg/kg dose cohorts; mOS for 20 mg/kg cohorts has not yet been reached Alignment with FDA on Phase 2 and Phase 3 trial design elements. Company expects to begin enrolling patients in Phase 2 in 2H 2025 SAFEbody option exercise |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a- 16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2025 Commission File Number: 001-39997 Adagene Inc. 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu Province, 215123 People’s Republic of China +86-512-8 |
|
| August 12, 2025 |
ADAGENE INC. INDEX TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Table of Contents Exhibit 99.2 ADAGENE INC. INDEX TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Unaudited Interim Condensed Consolidated Financial Statements PAGES Unaudited Interim Condensed Consolidated Balance Sheets as of December 31, 2024 and June 30, 2025 F-2 Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss for the Six Months Ended June 30, 202 |
|
| July 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a- 16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2025 Commission File Number: 001-39997 Adagene Inc. 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu Province, 215123 People’s Republic of China +86-512-877 |
|
| July 15, 2025 |
Exhibit 99.1 Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA - Alignment gained on Phase 2 inclusion/exclusion criteria, primary and secondary endpoints, and study design, including sample size and dosing regimen - Company expects to begin enrolling patients in P |
|
| July 1, 2025 |
Exhibit 99.1 Internal Adagene announces up to $25 million strategic investment from Sanofi - Sanofi to exercise option on third SAFEbody discovery program and sponsor combination clinical trial with muzastotug - Company expects proceeds to extend cash runway into 2027 SAN DIEGO and SUZHOU, China, July 1, 2025 (GLOBE NEWSWIRE) - Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company tran |
|
| July 1, 2025 |
Exhibit 4.1 FORM OF ADAGENE INC. CERTIFICATE OF DESIGNATIONS OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A NON-VOTING CONVERTIBLE PREFERRED SHARES PURSUANT TO ARTICLE 9 OF THE SEVENTH AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION OF ADAGENE INC. ADAGENE INC., an exempted company incorporated in the Cayman Islands (the “Company”), does hereby certify that the powers, preferences, |
|
| July 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Commission file number: 001-39997 Adagene Inc. (Exact Name of Registrant as Specified in Its Charter) 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu Province, 21 |
|
| July 1, 2025 |
Exhibit 10.1 Execution Version SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June 30, 2025, by and between Adagene Inc., an exempted company with limited liability incorporated in the Cayman Islands (the “Company”), and Sanofi Foreign Participations B.V., a private limited company incorporated in the Netherlands (the “Purchaser”). RECITALS A. |
|
| May 30, 2025 |
Adagene Inc. Up to US$100,000,000 of American Depositary Shares Representing Ordinary Shares TABLE OF CONTENTS As Filed Pursuant to Rule 424(b)(5) Registration No. 333-287161 PROSPECTUS SUPPLEMENT (To Prospectus dated May 30, 2025 ) Adagene Inc. Up to US$100,000,000 of American Depositary Shares Representing Ordinary Shares We have entered into a Sales Agreement, or sales agreement, with Leerink Partners LLC, or Leerink Partners, dated March 29, 2024, relating to the sale of American de |
|
| May 28, 2025 |
Adagene Inc. 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu Province, 215123 People’s Republic of China May 28, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Mr. Chris Edwards Mr. Tyler Howes Ms. Laura Crotty Re: Adagene Inc. Registration Statement |
|
| May 23, 2025 |
Davis Polk & Wardwell Hong Kong Solicitors The Hong Kong Club Building 3A Chater Road Hong Kong davispolk. |
|
| May 23, 2025 |
As filed with the Securities and Exchange Commission on May 23, 2025 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on May 23, 2025 Registration No. |
|
| May 22, 2025 |
Exhibit 99.1 Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting CTLA-4 inhibitor ADG126 can be dosed at 20 mg/kg Q6W in combination with pembrolizumab with <20% Grade 3 adverse events In combination with pembrolizumab, ADG126 showed a 29% co |
|
| May 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a- 16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2025 Commission File Number: 001-39997 Adagene Inc. 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu Province, 215123 People’s Republic of China +86-512-8777 |
|
| May 9, 2025 |
Exhibit 107 Calculation of Filing Fee Tables F-3 (Form Type) Adagene Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee(2) Carry For |
|
| May 9, 2025 |
As filed with the Securities and Exchange Commission on May 9, 2025 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on May 9, 2025 Registration No. |
|
| March 24, 2025 |
Exhibit 15.3 Nancy E. Taylor Tel 202.331.3133 Fax 202.261.0133 [email protected] March 24, 2025 Adagene Inc. 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu Province, 215123 People’s republic of China To Whom It May Concern: We consent to the references to our summary of opinions under the headings “Item 4.B. Business Overview—Regulation—United States Regulation” in |
|
| March 24, 2025 |
Exhibit 15.1 34/F, Tower 3, China Central Place, 77 Jianguo Road, Beijing 100025, China T: (86-10) 5809 1000 F: (86-10) 5809 1100 March 24, 2025 To: Adagene Inc. 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu Province, 215123 People’s republic of China (as the “Company”) Dear Sirs, We consent to the references to our firm under the headings “Item 3. Key Information |
|
| March 24, 2025 |
Exhibit 13.2 Certification by the Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Adagene Inc. (the “Company”) on Form 20-F for the year ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Man Kin (Raymond) Tam, Chief Financial Officer of the Company, certify |
|
| March 24, 2025 |
Exhibit 13.1 Certification by the Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Adagene Inc. (the “Company”) on Form 20-F for the year ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Peter Luo, Chief Executive Officer of the Company, certify, pursuant t |
|
| March 24, 2025 |
Exhibit 15.2 24 March 2025 Our Ref: MRC/KH/A6545-H22467 Adagene Inc. 4F, Building C14, No.218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu Province, 215123 People’s Republic of China Dear Sirs or Madam ADAGENE INC. Form 20-F We consent to the reference to our firm under the heading “Item 10.E. Taxation —Cayman Islands Taxation” and “Item 16.G. Corporate Governance” in the Annual Report on |
|
| March 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(B) OR 12(G) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) |
|
| March 24, 2025 |
Exhibit 12.2 Certification by the Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Man Kin (Raymond) Tam, certify that: 1. I have reviewed this annual report on Form 20-F of Adagene Inc. (the “company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statem |
|
| March 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a- 16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2025 Commission File Number: 001-39997 Adagene Inc. 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu Province, 215123 People’s Republic of China +86-512-87 |
|
| March 24, 2025 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.4 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-255250) and Form F-3 (No. 333-264486) of Adagene Inc. of our report dated March 24, 2025 relating to the financial statements, which appears in this Form 20-F. /s/PricewaterhouseCoopers Zhong Tian LLP Shanghai, the People’s Re |
|
| March 24, 2025 |
Exhibit 12.1 Certification by the Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Peter Luo, certify that: 1. I have reviewed this annual report on Form 20-F of Adagene Inc. (the “company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, i |
|
| March 24, 2025 |
Exhibit 11.2 Adagene Inc. Amended and Restated Statement of Policy Concerning Trading in Company Securities (Initially adopted in January 2021 and amended and restated in August 2023) TABLE OF CONTENTS Page No. I. SUMMARY OF POLICY CONCERNING TRADING IN COMPANY SECURITIES 1 II. THE USE OF INSIDE INFORMATION IN CONNECTION WITH TRADING IN SECURITIES 1 A. General Rule. 1 B. Who Does the Policy Apply |
|
| March 24, 2025 |
Exhibit 2.5 Description of Rights of Each Class of Securities Registered under Section 12 of the Securities Exchange Act of 1934 (the “Exchange Act”) American Depositary Shares (“ADSs”), each representing one and one quarter ordinary shares of Adagene Inc. (“our company” or “us”) are listed on the Nasdaq Global Market and the shares are registered under Section 12(b) of the Exchange Act. This exhi |
|
| March 24, 2025 |
Exhibit 99.1 Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update Muzastotug Phase 2 dose expansion in MSS CRC with a 20 mg/kg loading dose regimen shows 33% overall response rate with four confirmed partial responses SAFEbody technology utilized to create masked T cell engagers for potentially superior safety profile with enhanced therapeutic index Cash balance of $85.2 |
|
| February 4, 2025 |
EX-99.1 2 ex991.htm EXHIBIT 99.1 Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13G. Each of them is responsible for the timely filing of such statement and any amendments thereto, and for the completeness and accuracy of t |
|
| January 27, 2025 |
Exhibit 99.1 Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium Muzastotug (ADG126), an Anti-CTLA-4 SAFEbody® in Combination with pembrolizumab showed 33% overall response rate in microsatellite stable colorectal cancer Four confirmed partial responses out of twelve patient |
|
| January 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a- 16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2025 Commission File Number: 001-39997 Adagene Inc. 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu Province, 215123 People’s Republic of China +86-512- |
|
| November 7, 2024 |
ADAG / Adagene Inc. - Depositary Receipt (Common Stock) / Huang James - SC 13G/A Passive Investment SC 13G/A 1 d882300dsc13ga.htm SC 13G/A Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Adagene Inc. (Name of Issuer) Ordinary Shares (Title of Class of Securitie |
|
| November 7, 2024 |
Exhibit 99.1 Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - Improved safety and efficacy profiles for ADG126 versus ipilimumab dri |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K/A REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2024 Commission File Number: 001-39997 Adagene Inc. 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu Province, 215123 People’s Republic of China +86-51 |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a- 16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2024 Commission File Number: 001-39997 Adagene Inc. 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu Province, 215123 People’s Republic of China +86-512 |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K/A REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2024 Commission File Number: 001-39997 Adagene Inc. 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu Province, 215123 People’s Republic of China +86-51 |
|
| September 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a- 16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2024 Commission File Number: 001-39997 Adagene Inc. 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu Province, 215123 People’s Republic of China +86-51 |
|
| September 16, 2024 |
Exhibit 99.1 Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC) - Confirmed partial responses (PRs) doubled to four since ASCO GI in MSS CRC patients without liver and peritoneal metastases for ov |
|
| July 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a- 16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2024 Commission File Number: 001-39997 Adagene Inc. 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu Province, 215123 People’s Republic of China +86-512-877 |
|
| July 25, 2024 |
ADAGENE INC. INDEX TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Table of Contents Exhibit 99.2 ADAGENE INC. INDEX TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Unaudited Interim Condensed Consolidated Financial Statements PAGES Unaudited Interim Condensed Consolidated Balance Sheets as of December 31, 2023 and June 30, 2024 F-2 Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss for the Six Months Ended June 30, 202 |
|
| July 25, 2024 |
Exhibit 99.1 Adagene Reports Six Month Financial Results for 2024 and Provides Corporate Update - Potential best-in-class therapeutic index for lead candidate anti-CTLA-4 SAFEbody® ADG126 (muzastotug) with higher, more frequent and repeat dosing in combination with Merck’s anti-PD-1 therapy KEYTRUDA* (pembrolizumab) to unleash potential efficacy, while maintaining safety comparable to pembrolizuma |
|
| March 29, 2024 |
ADAGENE INC. COMPENSATION RECOUPMENT POLICY Exhibit 97 ADAGENE INC. COMPENSATION RECOUPMENT POLICY This Adagene Inc. Compensation Recoupment Policy (the “Policy”) has been adopted by the Board of Directors (the “Board”) of Adagene Inc. (the “Company”) on August 23, 2023. This Policy provides for the recoupment of certain executive compensation in the event of an accounting restatement resulting from material noncompliance with financial rep |
|
| March 29, 2024 |
Exhibit 13.1 Certification by the Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Adagene Inc. (the “Company”) on Form 20-F for the year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Peter Luo, Chief Executive Officer of the Company, certify, pursuant t |
|
| March 29, 2024 |
Exhibit 1.1 Adagene Inc. American Depositary Shares Each Representing 1.25 Ordinary Shares ($0.0001 par value per Ordinary Share) SALES AGREEMENT March 29, 2024 LEERINK PARTNERS LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: Adagene Inc., an exempted company incorporated with limited liability under the laws of the Cayman Islands (the “Company”), confirm |
|
| March 29, 2024 |
Exhibit 13.2 Certification by the Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Adagene Inc. (the “Company”) on Form 20-F for the year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Man Kin (Raymond) Tam, Chief Financial Officer of the Company, certify |
|
| March 29, 2024 |
Adagene Inc. Up to US$100,000,000 of American Depositary Shares Representing Ordinary Shares TABLE OF CONTENTS As Filed Pursuant to Rule 424(b)(5) Registration No. 333-264486 PROSPECTUS SUPPLEMENT (To Prospectus dated May 26, 2022 ) Adagene Inc. Up to US$100,000,000 of American Depositary Shares Representing Ordinary Shares We have entered into a Sales Agreement, or sales agreement, with Leerink Partners LLC, or Leerink Partners, dated March 29, 2024, relating to the sale of American de |
|
| March 29, 2024 |
Exhibit 15.2 29 March 2024 Our Ref: MRC/KH/A6545-H22467 Partners: Brett Basdeo John Cartwright Audrey Coker John Crook Mark Cummings James Gaden Thomas Granger Kristen Kwok Wing Lam William Lee Thomas Pugh Andrew Randall Victoria Raymond Rupen Shah Colette Wilkins KC Denise Wong *** * * * ***** **** ** ** * * ***** ** * ***** *** ** Adagene Inc. 4F, Building C14, No.218 Xinghu Street, Suzhou Indus |
|
| March 29, 2024 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.4 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (File No. 333-255250) and Form F-3 (File No. 333-264486) of Adagene Inc. of our report dated March 29, 2024 relating to the financial statements, which appears in this Form 20-F. /s/PricewaterhouseCoopers Zhong Tian LLP Shanghai, the P |
|
| March 29, 2024 |
Exhibit 15.3 Nancy E. Taylor Tel 202.331.3133 Fax 202.261.0133 [email protected] March 29, 2024 Adagene Inc. 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu Province, 215123 People’s republic of China To Whom It May Concern: We consent to the references to our summary of opinions under the headings “Item 4.B. Business Overview—Regulation—United States Regulation” in |
|
| March 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(B) OR 12(G) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) |
|
| March 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2024 Commission File Number: 001-39997 Adagene Inc. (Exact Name of Registrant as Specified in Its Charter) 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu |
|
| March 29, 2024 |
Exhibit 15.1 34/F, Tower 3, China Central Place, 77 Jianguo Road, Beijing 100025, China T: (86-10) 5809 1000 F: (86-10) 5809 1100 March 29, 2024 To: Adagene Inc. 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu Province, 215123 People’s republic of China (as the “Company”) Dear Sirs, We consent to the references to our firm under the headings “Item 3. Key Information |
|
| March 29, 2024 |
Exhibit 99.1 Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update - Data for masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) highlight best-in-class therapeutic index and demonstrate clinical benefits in metastatic microsatellite-stable (MSS) colorectal cancer (CRC) with higher, more frequent and repeat dosing of anti-CTLA-4 therapy in combination with anti-PD-1 – - Ongo |
|
| March 29, 2024 |
Exhibit 2.5 Description of Rights of Each Class of Securities Registered under Section 12 of the Securities Exchange Act of 1934 (the “Exchange Act”) American Depositary Shares (“ADSs”), each representing one and one quarter ordinary shares of Adagene Inc. (“our company” or “us”) are listed on the Nasdaq Global Market and the shares are registered under Section 12(b) of the Exchange Act. This exhi |
|
| March 29, 2024 |
Exhibit 12.1 Certification by the Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Peter Luo, certify that: 1. I have reviewed this annual report on Form 20-F of Adagene Inc. (the "company"); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, i |
|
| March 29, 2024 |
Exhibit 12.2 Certification by the Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Man Kin (Raymond) Tam, certify that: 1. I have reviewed this annual report on Form 20-F of Adagene Inc. (the “company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statem |
|
| March 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2024 Commission File Number: 001-39997 Adagene Inc. (Exact Name of Registrant as Specified in Its Charter) 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu |
|
| March 1, 2024 |
AGREEMENT AS TO JOINT FILING OF SCHEDULE 13D EX-99.B 3 tm247478d1ex99-b.htm EXHIBIT B Exhibit B AGREEMENT AS TO JOINT FILING OF SCHEDULE 13D The undersigned hereby agree that they are filing jointly pursuant to Rule 13-d-1(k)(1) of the Securities Exchange Act of 1934, as amended, with respect to ordinary shares of Adagene Inc., and that all subsequent amendments to this statement on Schedule 13D may be filed on behalf of each of the undersig |
|
| March 1, 2024 |
EX-99.A 2 tm247478d1ex99-a.htm EXHIBIT A Exhibit A Concert Party Agreement This Concert Party Agreement (hereinafter this “Agreement”) is executed by and among the following parties on December 14, 2020: (1) Mr. Peter (Peizhi) Luo (the “Founder”); (2) Mr. Fangyong (Felix) Du (“Mr. Du”); (3) Ms. Ping Ren (“Ms. Ren”) (4) Ms. Hua Gong (“Ms. Gong”); (5) Ms. JC Xu (“Ms. Xu”); (6) Mr. Qinghai Zhao (“Mr. |
|
| March 1, 2024 |
ADAG / Adagene Inc. - Depositary Receipt (Common Stock) / Luo Peter - SC 13D/A Activist Investment SC 13D/A 1 tm247478d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 2)* Adagene, Inc. (Name of Issuer) Ordinary shares, par value USD $0.0001 per share (Title of Class of Securities |
|
| February 9, 2024 |
Exhibit 99.2 Company Overview & ADG126 MSS CRC Clinical Results February 2024 Disclaimer and Cautionary Note on Forward-Looking Statements The following presentation has been prepared by Adagene Inc. (“Adagene” or the “Company”) solely for informational purposes and should not be construed to be, directly or indirectly, in whole or in part, an offer to buy or sell and/or an invitation and/or a rec |
|
| February 9, 2024 |
Exhibit 99.1 Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC) - Interim data from additional MSS CRC patients dosed at 10 mg/kg every three weeks (Q3W) in combina |
|
| February 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2024 Commission File Number: 001-39997 Adagene Inc. (Exact Name of Registrant as Specified in Its Charter) 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiang |
|
| January 19, 2024 |
EX-99 2 d726976dex99.htm EX-99 Exhibit 99 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13G. Each of them is responsible for the timely filing of such statement and any amendments thereto, and for the completeness and accuracy of the i |
|
| January 19, 2024 |
ADAG / Adagene Inc. - Depositary Receipt (Common Stock) / Huang James - SC 13G Passive Investment SC 13G 1 d726976dsc13g.htm SC 13G Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Adagene Inc. (Name of Issuer) Ordinary Shares (Title of Class of Securities) 005 |
|
| January 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2024 Commission File Number: 001-39997 Adagene Inc. (Exact Name of Registrant as Specified in Its Charter) 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangs |
|
| January 16, 2024 |
Exhibit 99.1 Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC) - Data from first tranche of MSS CRC patients treated with ADG126 10 mg/kg every three weeks (Q3W) in dose expansion showed clinical benefit including confirmed respons |
|
| November 3, 2023 |
Exhibit 99.1 Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023 - MSS CRC case examples reinforce optimal dosing regimen in ongoing phase 2 dose expansion, with a confirmed partial response at ADG126 10 mg/kg every three weeks plus pembrolizumab – - Integrated pharmacokinetic and clinical data analyses support the mechanism |
|
| November 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2023 Commission File Number: 001-39997 Adagene Inc. (Exact Name of Registrant as Specified in Its Charter) 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiang |
|
| September 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2023 Commission File Number: 001-39997 Adagene Inc. (Exact Name of Registrant as Specified in Its Charter) 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jian |
|
| August 31, 2023 |
Exhibit 99.1 Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update - Best-in-class anti-CTLA-4 candidates designed for more than 30-fold increase in therapeutic index, addressing patient populations where CTLA-4-mediated Treg depletion is essential for efficacy – - Strong efficacy signal observed in MSS CRC phase 2 single arm study for SAFEbody® ADG126 in combination w |
|
| August 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2023 Commission File Number: 001-39997 Adagene Inc. (Exact Name of Registrant as Specified in Its Charter) 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu |
|
| July 10, 2023 |
July 10, 2023 Re: Adagene Inc. Annual Report on Form 20-F Filed April 28, 2023 File No. 001-39997 Ms. Lynn Dicker Mr. Kevin Kuhar Mr. Kyle Wiley Mr. Christopher Dunham Mr. Jimmy McNamara Mr. Tim Buchmiller Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Dear Lynn Dicker, Kevin Kuhar, Kyle Wiley, Christopher Dun |
|
| July 7, 2023 |
Unleashing Anti - CTLA - 4 Therapy By Enhancing the Therapeutic Index July 2023 Exhibit 99.1 Unleashing Anti - CTLA - 4 Therapy By Enhancing the Therapeutic Index July 2023 Disclaimer and Cautionary Note on Forward - Looking Statements The following presentation has been prepared by Adagene Inc . (“Adagene” or the “Company”) solely for informational purposes and should not be construed to be, directly or indirectly, in whole or in part, an offer to buy or sell and/or an invit |
|
| July 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2023 Commission File Number: 001-39997 Adagene Inc. (Exact Name of Registrant as Specified in Its Charter) 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu P |
|
| June 16, 2023 |
June 16, 2023 Re: Adagene Inc. Annual Report on Form 20-F Filed April 28, 2023 File No. 001-39997 Ms. Lynn Dicker Mr. Kevin Kuhar Mr. Kyle Wiley Mr. Christopher Dunham Mr. Jimmy McNamara Mr. Tim Buchmiller Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Dear Lynn Dicker, Kevin Kuhar, Kyle Wiley, Christopher Dun |
|
| May 4, 2023 |
Exhibit 99.1 Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug Conjugate SAN DIEGO and SUZHOU, China, May 4, 2023 – Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies today announced ac |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2023 Commission File Number: 001-39997 Adagene Inc. (Exact Name of Registrant as Specified in Its Charter) 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu Pr |
|
| April 28, 2023 |
Exhibit 15.1 34/F, Tower 3, China Central Place, 77 Jianguo Road, Beijing 100025, China T: (86-10) 5809 1000 F: (86-10) 5809 1100 April 28 2023 To: Adagene Inc. 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu Province, 215123 People’s republic of China (as the “Company”) Dear Sirs, We consent to the references to our firm under the headings “Item 3. Key Information— |
|
| April 28, 2023 |
Exhibit 13.2 Certification by the Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Adagene Inc. (the “Company”) on Form 20-F for the year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Man Kin (Raymond) Tam, Chief Financial Officer of the Company, certify |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2023 Commission File Number: 001-39997 Adagene Inc. (Exact Name of Registrant as Specified in Its Charter) 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu |
|
| April 28, 2023 |
Exhibit 12.1 Certification by the Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Peter (Peizhi) Luo, certify that: 1. I have reviewed this annual report on Form 20-F of Adagene Inc. (the "company"); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statement |
|
| April 28, 2023 |
Exhibit 15.2 28 April 2023Our Ref: NASD/KH/A6545-H22467 Adagene Inc. 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu Province, 215123 People’s republic of China Dear Sirs or Madam ADAGENE INC. FORM 20-F We consent to the reference to our firm under the heading “Item 10.E. Taxation —Cayman Islands Taxation” and “Item 16.G. Corporate Governance” in the Annual Report o |
|
| April 28, 2023 |
Exhibit 2.5 Description of Rights of Each Class of Securities Registered under Section 12 of the Securities Exchange Act of 1934 (the “Exchange Act”) American Depositary Shares (“ADSs”), each representing one and one quarter ordinary shares of Adagene Inc. (“our company” or “us”) are listed on the Nasdaq Global Market and the shares are registered under Section 12(b) of the Exchange Act. This exhi |
|
| April 28, 2023 |
Exhibit 13.1 Certification by the Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Adagene Inc. (the “Company”) on Form 20-F for the year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Peter (Peizhi) Luo, Chief Executive Officer of the Company, certify, p |
|
| April 28, 2023 |
Exhibit 15.5 April 28 2023 VIA EDGAR Division of Corporation Finance U.S. Securities & Exchange Commission 100 F Street, NE Washington, D.C. 20549 Re: Adagene Inc. Submission under the Item 16I(a) of Form 20-F Attn: Division of Corporation Finance Office of Life Sciences Dear Sir/Madam, In compliance with the Holding Foreign Companies Accountable Act, Adagene Inc. (the “Company”) is submitting via |
|
| April 28, 2023 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.4 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (File No. 333-255250) and Form F-3 (File No. 333-264486) of Adagene Inc. of our report dated April 28, 2023 relating to the financial statements, which appears in this Form 20-F. /s/PricewaterhouseCoopers Zhong Tian LLP Shanghai, the P |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(B) OR 12(G) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) |
|
| April 28, 2023 |
Adagene Announces Updates to its Board of Directors Exhibit 99.1 Adagene Announces Updates to its Board of Directors SAN DIEGO and SUZHOU, China, April 28, 2023 – Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies today announced updates to its board of directors (the “Board”), including the following: ● Mervyn Turner, Ph.D., i |
|
| April 28, 2023 |
Exhibit 15.3 Nancy E. Taylor Tel 202.331.3133 Fax 202.261.0133 [email protected] April 28 2023 Adagene Inc. 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu Province, 215123 People’s republic of China To Whom It May Concern: We consent to the references to our summary of opinions under the headings “Item 4.B. Business Overview—Regulation—United States Regulation” in |
|
| April 28, 2023 |
Exhibit 12.2 Certification by the Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Man Kin (Raymond) Tam, certify that: 1. I have reviewed this annual report on Form 20-F of Adagene Inc. (the “company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statem |
|
| April 18, 2023 |
Exhibit 99.1 Adagene Presents Clinical Data for Anti-CTLA-4 SAFEbody® ADG126 Reinforcing Best-in-Class Safety Profile at Repeat Doses and Showing Early Efficacy Profile in Advanced/Metastatic Solid Tumors - Results of dose escalation portion from phase 1b/2 trials of ADG126 in combination with anti-PD-1 therapies, including confirmed clinical responses, pave way for dose expansion in specific tumo |
|
| April 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2023 Commission File Number: 001-39997 Adagene Inc. (Exact Name of Registrant as Specified in Its Charter) 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu |
|
| March 28, 2023 |
Exhibit 99.1 28 March Adagene Reports Full Year 2022 Financial Results and Provides Corporate Update - Clinical data for wholly-owned anti-CTLA-4 franchise show best-in-class safety profiles for unmasked and masked candidates, unlocking the full therapeutic benefit of anti-CTLA-4 in combination with anti-PD-1 and beyond - - Roche sponsoring randomized, multi-national phase 1b/2 trial of novel trip |
|
| March 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2023 Commission File Number: 001-39997 Adagene Inc. (Exact Name of Registrant as Specified in Its Charter) 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu |
|
| February 17, 2023 |
ADAG / Adagene Inc / Luo Peter - AMENDMENT NO. 1 Activist Investment SC 13D/A 1 dp189092sc13d-a.htm AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 1)* Adagene, Inc. (Name of Issuer) Ordinary shares, par value USD $0.0001 per share (Title of Class of Secu |
|
| February 6, 2023 |
ADAG / Adagene Inc / JSR Ltd - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Adagene Inc. (Name of Issuer) Ordinary shares, par value US$0.0001 per share, presented by American Depositary Share (Title of Class of Securities) 005329 107** (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Chec |
|
| January 9, 2023 |
6-K 1 tm232685d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2023 Commission File Number: 001-39997 Adagene Inc. (Exact Name of Registrant as Specified in Its Charter) 4F, Building C14, No. 218 Xinghu Street, Suzho |
|
| January 9, 2023 |
Exhibit 99.1 Adagene Announces Interim Data Demonstrating Safety and Confirmed Clinical Responses of Anti-CTLA-4 SAFEbody® ADG126 up to 10 mg/kg with Repeat Cycles in Combination with Anti-PD-1 Therapy from Dose Escalation Portion of Phase 1b/2 Trial - No dose-limiting toxicities observed when ADG126 combined up to 10 mg/kg with repeat cycles, highlighting compelling safety profile with SAFEbody p |
|
| December 16, 2022 |
Exhibit 99.1 Adagene Announces Clinical Trial Collaboration to Evaluate Anti-CTLA-4 SAFEbody? ADG126 in Combination with Roche?s Standard-of-Care for First-Line Advanced Liver Cancer SAN DIEGO and SUZHOU, China, December 16, 2022 ? Adagene Inc. (?Adagene?) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced a clinical trial collaboratio |
|
| December 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2022 Commission File Number: 001-39997 Adagene Inc. (Exact Name of Registrant as Specified in Its Charter) 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiang |
|
| November 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2022 Commission File Number: 001-39997 Adagene Inc. (Exact Name of Registrant as Specified in Its Charter) 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiang |
|
| November 21, 2022 |
Adagene Appoints Cuong Do to Board of Directors and Audit Committee Exhibit 99.1 Adagene Appoints Cuong Do to Board of Directors and Audit Committee SAN DIEGO and SUZHOU, China, November 21, 2022 ? Adagene Inc. (?Adagene?) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Cuong Do, MBA, to Adagene?s board of directors (the ?Board?) as an independent director. He will also serve as a |
|
| September 12, 2022 |
Exhibit 99.1 Adagene Presents Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-Tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody? ADG126 in Patients with Advanced Tumors - Best-in-class profile demonstrated with repeat dosing across dose levels - - Antitumor activity observed in cold tumors with steady accumulation of activated ADG126 - - On track in 2022 to |
|
| September 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2022 Commission File Number: 001-39997 Adagene Inc. (Exact Name of Registrant as Specified in Its Charter) 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jian |
|
| August 31, 2022 |
Exhibit 99.1 Adagene Reports Financial Results for the Six Months Ended June 30, 2022 and Provides Corporate Updates - Topline data for anti-CTLA-4 antibody, ADG116, shows compelling clinical safety and complete and partial responses as both a single agent and in combination with anti-PD-1 therapy; results to be presented at SITC 2022 - - Masked, anti-CTLA-4 antibody, ADG126, safely dosed repeated |
|
| August 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2022 Commission File Number: 001-39997 Adagene Inc. (Exact Name of Registrant as Specified in Its Charter) 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu |
|
| June 29, 2022 |
Adagene Announces Authorization of Share Repurchase Program up to US$10 Million Exhibit 99.1 Adagene Announces Authorization of Share Repurchase Program up to US$10 Million SAN DIEGO, Calif. and SUZHOU, China, June 29, 2022 ? Adagene Inc. (?Adagene?) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that its board of directors has authorized a share repurchase program under which, Adagene may repurchase up |
|
| June 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2022 Commission File Number: 001-39997 Adagene Inc. (Exact Name of Registrant as Specified in Its Charter) 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu P |
|
| May 26, 2022 |
6-K 1 tm2216873d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2022 Commission File Number: 001-39997 Adagene Inc. (Exact Name of Registrant as Specified in Its Charter) 4F, Building C14, No. 218 Xinghu Street, Suzhou I |
|
| May 26, 2022 |
EX-99.1 2 tm2216873d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Adagene Announces Publication at ASCO of Interim Monotherapy Dose Escalation Data Showing Compelling Safety Profile of Anti-CTLA-4 SAFEbody® ADG126, with Repeat Dosing Across Dose Levels - First clinical data demonstrating potential of SAFEbody technology platform to create best-in-class therapeutics - - Additional data from ongoing ADG126 |
|
| May 24, 2022 |
Adagene Inc. 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu Province, 215123 People?s Republic of China May 24, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Mr. Alan Campbell ????Ms. Celeste Murphy Re:???????????Adagene Inc. Registration Statement on Form F-3 Fil |
|
| May 20, 2022 |
As filed with the Securities and Exchange Commission on May 20, 2022 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on May 20, 2022 Registration No. |
|
| May 13, 2022 |
Davis Polk & Wardwell Hong Kong Solicitors The Hong Kong Club Building 3A Chater Road Hong Kong davispolk. |
|
| May 13, 2022 |
As filed with the Securities and Exchange Commission on May 13, 2022 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on May 13, 2022 Registration No. |
|
| May 2, 2022 |
ADAGENE INC. 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu Province, 215123 People?s Republic of China May 2, 2022 VIA EDGAR Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 USA RE: Delaying Amendment for Adagene Inc. Registration Statement on Form F-3 (File No. 333-264486) Ladies and Gentlemen: Referenc |
|
| April 29, 2022 |
ADAG / Adagene Inc / Luo Peter - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2(a) (Amendment No. )* Adagene, Inc. (Name of Issuer) Ordinary shares, par value USD $0.0001 per share (Title of Class of Securities) 005329 107** (CUSIP Number) Peter Luo Adag |
|
| April 29, 2022 |
AGREEMENT AS TO JOINT FILING OF SCHEDULE 13D CUSIP: 005329 107** Page 1 of 1 Page EXHIBIT 99.1 AGREEMENT AS TO JOINT FILING OF SCHEDULE 13D The undersigned hereby agree that they are filing jointly pursuant to Rule 13-d-1(k)(1) of the Securities Exchange Act of 1934, as amended, with respect to ordinary shares of Adagene Inc., and that all subsequent amendments to this statement on Schedule 13D may be filed on behalf of each of the undersign |
|
| April 26, 2022 |
Calculation of Filing Fee Tables EX-FILING FEES 6 tm2213007d2ex-filingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form F-3 (Form Type) Adagene Inc. (Exact Name of Registrant as Specified in its Charter) Not Applicable (Translation of Registrant’s Name into English) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registe |
|
| April 26, 2022 |
Exhibit 13.1 Certification by the Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Adagene Inc. (the “Company”) on Form 20-F for the year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Peter (Peizhi) Luo, Chief Executive Officer of the Company, certify, p |
|
| April 26, 2022 |
EX-4.16 2 adag-20211231xex4d16.htm EXHIBIT 4.16 Exhibit 4.16 *** CERTAIN IDENTIFIED INFORMATION (INDICATED BY THREE ASTERISKS IN BRACKETS) HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. COLLABORATION AND LICENSE AGREEMENT THIS COLLABORATION AND LICENSE AGREEMENT (the “Agreement”) is entered into as of Februa |
|
| April 26, 2022 |
Consent of PricewaterhouseCoopers Zhong Tian LLP, Independent Registered Public Accounting Firm Exhibit 15.4 ? CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM ? We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (File No. 333-255250) of Adagene Inc. of our report dated April 26, 2022 relating to the financial statements, which appears in this Form 20-F. ? ? /s/PricewaterhouseCoopers Zhong Tian LLP ? Shanghai, the People?s Republic of China |
|
| April 26, 2022 |
Exhibit 13.2 Certification by the Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Adagene Inc. (the “Company”) on Form 20-F for the year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Man Kin (Raymond) Tam, Chief Financial Officer of the Company, certify |
|
| April 26, 2022 |
? Exhibit 15.3 Nancy E. Taylor Tel 202.331.3133 Fax 202.261.0133 [email protected] ? April 26, 2022 Adagene Inc. 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu Province, People?s Republic of China To Whom it May Concern: We consent to the references to our summary of opinions under the headings ?Item 4.B. Business Overview?Regulation?United States Regulation? in Ad |
|
| April 26, 2022 |
Exhibit 15.1 ? 10/F, Tower B, CPIC Plaza, No. 28 Fengsheng Lane, Xicheng District, Beijing 100032, China Tel: 86 10 5776 3888 Fax: 86 10 5776 3777 April 26, 2022 To: Adagene Inc. 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu Province, People?s Republic of China (as the ?Company?) Dear Sirs, We consent to the references to our firm under the headings ?Item 3. Key I |
|
| April 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 26, 2022 |
Power of Attorney (included in signature page of this registration statement) TABLE OF CONTENTS As filed with the Securities and Exchange Commission on April 26, 2022 Registration No. |
|
| April 26, 2022 |
Consent of Walkers (Hong Kong) Exhibit 15.2 ? ? ? ? ? April 26, 2022 Our Ref: NASD/KH/A6545-H22467 ? ? ? Adagene Inc. ? ? 4F, Building C14, No.218 ? ? Xinghu Street, Suzhou Industrial Park ? ? Suzhou, Jiangsu Province, 215123 ? ? People?s Republic of China ? ? ? Dear Sirs or Madam ADAGENE INC. FORM 20-F We consent to the reference to our firm under the heading ?Item 10.E. Taxation ?Cayman Islands Taxation? and ?Item 16.G. Corpo |
|
| April 26, 2022 |
Exhibit 12.1 Certification by the Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Peter (Peizhi) Luo, certify that: 1. I have reviewed this annual report on Form 20-F of Adagene Inc. (the "company"); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statement |
|
| April 26, 2022 |
Exhibit 12.2 Certification by the Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Man Kin (Raymond) Tam, certify that: 1. I have reviewed this annual report on Form 20-F of Adagene Inc. (the “company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statem |
|
| April 8, 2022 |
Exhibit 99.1 Adagene Presents Data Demonstrating First and Best-in-Class Potential for Differentiated Preclinical Antibody Candidates at American Association for Cancer Research (AACR) Annual Meeting 2022 - Poster presentations showcase SAFEbody? precision masking technology applicability across targets and modalities - - IND or equivalent filings planned for two new product candidates in 2022, in |
|
| April 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2022 Commission File Number: 001-39997 Adagene Inc. (Exact Name of Registrant as Specified in Its Charter) 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2022 Commission File Number: 001-39997 Adagene Inc. (Exact Name of Registrant as Specified in Its Charter) 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu |
|
| March 31, 2022 |
Exhibit 99.1 Adagene Reports Full Year 2021 Financial Results and Provides Corporate Update - 2022 clinical data readouts on track to show potential best-in-class safety profile for anti-CTLA-4 programs (ADG116, ADG126) with PD-1 for proven and new indications, thereby enabling greater efficacy through higher and more frequent dosing - - Advanced three wholly-owned clinical programs both in single |
|
| March 16, 2022 |
Exhibit 99.1 Adagene Announces FDA Clearance to Proceed with Phase 1b/2 Trial of Anti-CTLA-4 ADG126 SAFEbody? in Combination Therapy With Anti-PD-1 Antibody Pembrolizumab - ADG126-P001 trial being initiated at multiple sites in U.S. and Asia Pacific ? - First SAFEbody candidate to advance into combination clinical trial, building on strong single-agent clinical profile ? SAN DIEGO and SUZHOU, Chin |
|
| March 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2022 Commission File Number: 001-39997 Adagene Inc. (Exact Name of Registrant as Specified in Its Charter) 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu |
|
| March 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2022 Commission File Number: 001-39997 Adagene Inc. (Exact Name of Registrant as Specified in Its Charter) 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu |
|
| March 9, 2022 |
Exhibit 99.1 Adagene Announces Four Poster Presentations on Robust Preclinical Pipeline of Antibody-Based Therapeutics at Upcoming American Association for Cancer Research (AACR) Annual Meeting - New IND-enabling programs reinforce commitment to build a deep, broad and differentiated pipeline that transforms cancer immunotherapy leveraging company?s AI-powered platform - - SAFEbody? precision mask |
|
| March 2, 2022 |
Exhibit 99.1 Adagene Announces SAFEbody? Multi-Target Collaboration with Sanofi for Novel Masked Immuno-Oncology Antibody Candidates - Total potential transaction value of $2.5 billion plus royalties - SAN DIEGO and SUZHOU, China, March 2, 2022 ? Adagene Inc. (?Adagene?) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced a collaboratio |
|
| March 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2022 Commission File Number: 001-39997 Adagene Inc. (Exact Name of Registrant as Specified in Its Charter) 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu |
|
| February 11, 2022 |
ADAG / Adagene Inc / GENERAL ATLANTIC LLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Adagene Inc. (Name of Issuer) Ordinary shares, par value US$0.0001 per share (Title of Class of Securities) 005329107** (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| February 9, 2022 |
Exhibit A Joint Filing Agreement The undersigned hereby agrees that they are filing jointly pursuant to Rule 13-d-1(k)(1) of the Securities Exchange Act of 1934, as amended, with respect to ordinary shares of Adagene Inc. |
|
| February 9, 2022 |
ADAG / Adagene Inc / Luo Peter - FORM SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Adagene Inc. (Name of Issuer) Ordinary shares, par value US$0.0001 per share, presented by American Depositary Share (Title of Class of Securities) 005329 107** (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check |
|
| February 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2022 Commission File Number: 001-39997 Adagene Inc. (Exact Name of Registrant as Specified in Its Charter) 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiang |
|
| February 3, 2022 |
Adagene Announces Board and Management Appointments to Support Pipeline Growth Exhibit 99.1 Adagene Announces Board and Management Appointments to Support Pipeline Growth SAN DIEGO and SUZHOU, China, February 2, 2022 ? Adagene Inc. (?Adagene?) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced board and management appointments aimed at supporting the company?s pipeline growth and corporate development. The appoin |
|
| January 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2022 Commission File Number: 001-39997 Adagene Inc. (Exact Name of Registrant as Specified in Its Charter) 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangs |
|
| January 27, 2022 |
Exhibit 99.1 Adagene Announces First Patient Dosed with Novel, Proprietary Combination of Anti-CD137 Agonist, ADG106, and Anti-CTLA-4 Monoclonal Antibody, ADG116 SAN DIEGO and SUZHOU, China, January 27, 2022 - Adagene Inc. (?Adagene?) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced the first patient has been dosed in a combina |
|
| January 26, 2022 |
ADAG / Adagene Inc / JSR Ltd - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Adagene Inc. (Name of Issuer) Ordinary shares, par value US$0.0001 per share, presented by American Depositary Share (Title of Class of Securities) 005329 107** (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check |
|
| January 26, 2022 |
ADAG / Adagene Inc / WuXi PharmaTech Healthcare Fund I L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Adagene Inc. (Name of Issuer) Ordinary shares, par value US$0.0001 per share, presented by American Depositary Share (Title of Class of Securities) 005329 107** (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check |
|
| January 19, 2022 |
Exhibit 99.1 Adagene Expands Scientific and Strategic Advisory Board with Appointment of David Gandara, M.D. - Dr. Gandara, Professor and Senior Advisor to the Thoracic Oncology Program at University of California Davis, brings deep expertise and strategic vision in cancer drug and biomarker development- SAN DIEGO and SUZHOU, China, January 19, 2022 ? Adagene Inc. (?Adagene?) (Nasdaq: ADAG), a bio |
|
| January 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2022 Commission File Number: 001-39997 Adagene Inc. (Exact Name of Registrant as Specified in Its Charter) 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangs |
|
| January 13, 2022 |
Exhibit 99.1 Adagene Announces First Patients with Advanced Non-Small Cell Lung Cancer Dosed in Phase 1b/2 Clinical Trial of ADG106 in Combination with Nivolumab in Singapore - Clinical trial to be conducted at the National University Cancer Institute, Singapore and the National Cancer Centre Singapore, in Collaboration with the Singapore Translational Cancer Consortium- SAN DIEGO and SUZHOU, Chin |
|
| January 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2022 Commission File Number: 001-39997 Adagene Inc. (Exact Name of Registrant as Specified in Its Charter) 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangs |
|
| January 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2022 Commission File Number: 001-39997 Adagene Inc. (Exact Name of Registrant as Specified in Its Charter) 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangs |
|
| January 12, 2022 |
Exhibit 99.1 Company Overview January 2022 Disclaimer and Cautionary Note on Forward - Looking Statements The following presentation has been prepared by Adagene Inc . (? Adagene ? or the ?Company?) solely for informational purposes and should not be construed to be, directly or indirectly, in whole or in part, an offer to buy or sell and/or an invitation and/or a recommendation and/or a solicitat |
|
| December 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 144 /A NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933 ATTENTION: Transmit for filing 3 copies of this form concurrently with either placing an order with a broker to execute sale or executing a sale directly with a market maker. OMB APPROVAL OMB Number: 3235-0101 Expires: July |
|
| December 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number: 3235-0101 Expires: July 31, 2023 Estimated average burden hours per response 1.0 FORM 144 SEC USE ONLY NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933 DOCUMENT SEQUENCE NO. ATTENTION: Transmit for filing 3 copies of this form concurrently with either placing |
|
| December 22, 2021 |
EX-99.1 2 tm2136118d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Adagene Achieves Key Milestone in Collaboration with Exelixis for SAFEbody® Novel Masked Antibody-Drug Conjugate Candidates - Successful nomination of lead SAFEbody candidates triggers milestone payment - SAN DIEGO and SUZHOU, China, December 22, 2021 – Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a biopharmaceutical company committed to transf |
|
| December 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2021 Commission File Number: 001-39997 Adagene Inc. (Exact Name of Registrant as Specified in Its Charter) 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiang |
|
| December 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2021 Commission File Number: 001-39997 Adagene Inc. (Exact Name of Registrant as Specified in Its Charter) 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiang |
|
| December 14, 2021 |
Exhibit 99.1 Adagene Presents Preclinical Data Showcasing Best-in-Class Profiles for ADG153, an Anti-CD47 SAFEbody? and ADG152, a CD20xCD3 Bispecific T-cell Engager POWERbody? - Posters presented at the 63rd American Society of Hematology Annual Meeting - SAN DIEGO and SUZHOU, China, December 13, 2021 ? Adagene Inc. (?Adagene?) (Nasdaq: ADAG), a biopharmaceutical company committed to transforming |
|
| December 7, 2021 |
Exhibit 99.1 Adagene Presents Clinical Data Demonstrating Strong Safety and Early Signals of Efficacy in Cold Tumors Including Pancreatic and Ovarian Cancers for Anti-CTLA-4 Monoclonal Antibody, ADG116, at ESMO-IO 2021 - Additional highlights include pharmacodynamic biomarker analyses from ongoing trial of anti-CD137 antibody, ADG106, in combination with anti-PD-1 toripalimab - SAN DIEGO and SUZHO |
|
| December 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2021 Commission File Number: 001-39997 Adagene Inc. (Exact Name of Registrant as Specified in Its Charter) 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiang |
|
| December 6, 2021 |
Exhibit 99.1 Adagene Presents Clinical Data Demonstrating Strong Safety and Early Signals of Efficacy in Treatment-Resistant Tumors for Anti-CTLA-4 Monoclonal Antibody, ADG116, at ESMO-IO 2021 - Additional highlights include pharmacodynamic biomarker analyses from ongoing trial of anti-CD137 antibody, ADG106, in combination with anti-PD-1 toripalimab - SAN DIEGO and SUZHOU, China, December 6, 2021 |
|
| December 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2021 Commission File Number: 001-39997 Adagene Inc. (Exact Name of Registrant as Specified in Its Charter) 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiang |
|
| November 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2021 Commission File Number: 001-39997 Adagene Inc. (Exact Name of Registrant as Specified in Its Charter) 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiang |
|
| November 29, 2021 |
Exhibit 99.1 Adagene Announces FDA Clearance of IND for Phase 1b/2 Trial of Anti-CTLA-4 Monoclonal Antibody ADG116 in Combination Therapy with Anti-PD-1 Antibody Pembrolizumab - ADG116-P001 trial being initiated at multiple sites with dosing to begin early 2022 - SAN DIEGO and SUZHOU, China, November 29, 2021 ? Adagene Inc. (?Adagene?) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceu |
|
| November 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2021 Commission File Number: 001-39997 Adagene Inc. (Exact Name of Registrant as Specified in Its Charter) 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiang |
|
| November 23, 2021 |
EX-99.1 2 tm2133752d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Adagene Announces Poster Presentations of Clinical Data for Two Novel Antibody Programs at ESMO Immuno-Oncology Congress 2021 SAN DIEGO and SUZHOU, China, November 22, 2021 – Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel a |
|
| November 4, 2021 |
EX-99.1 2 tm2131941d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Adagene Unveils Preclinical Data from Two Transformative Antibody Programs at Upcoming American Society of Hematology (ASH) Annual Meeting - Presentations demonstrate compelling preclinical differentiation of an anti-CD47 antibody and a CD20xCD3 bispecific T-cell engager, both leveraging SAFEbody™ technology – - Both candidates designed to |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2021 Commission File Number: 001-39997 Adagene Inc. (Exact Name of Registrant as Specified in Its Charter) 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiang |
|
| October 27, 2021 |
EX-99.1 2 tm2130933d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Adagene Establishes Collaboration for Clinical Trial of ADG106 in Combination with Nivolumab in Patients with Non-Small Cell Lung Cancer in Singapore - Phase 1b/2 trial to be conducted at the National University Cancer Institute, Singapore and the National Cancer Centre Singapore, in Collaboration with the Singapore Translational Cancer Con |
|
| October 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2021 Commission File Number: 001-39997 Adagene Inc. (Exact Name of Registrant as Specified in Its Charter) 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangs |
|
| August 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2021 Commission File Number: 001-39997 Adagene Inc. (Exact Name of Registrant as Specified in Its Charter) 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu |
|
| August 26, 2021 |
EX-99.1 2 tm2125804d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Adagene Reports Financial Results for the Six Months Ended June 30, 2021 and Provides Corporate Updates - Established three clinical collaborations with Merck to conduct global combination trials with pembrolizumab for three clinical-stage oncology candidates - - Evidence of ADG106 efficacy with favorable safety profile shown in monotherapy |
|
| August 19, 2021 |
Exhibit 99.1 Adagene Announces the Third Clinical Trial Collaboration with Merck to Advance Anti-CD137 Agonist, ADG106, in Combination Therapy with KEYTRUDA?(pembrolizumab) -Collaboration to evaluate NEObody? product candidate, ADG106, in combination with KEYTRUDA? for patients with advanced or metastatic solid and/or hematological malignancies SAN FRANCISCO, Calif., August 19, 2021 ? Adagene Inc. |
|
| August 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2021 Commission File Number: 001-39997 Adagene Inc. (Exact Name of Registrant as Specified in Its Charter) 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu |
|
| August 12, 2021 |
Exhibit 99.1 Adagene Announces Appointment of Interim Chief Medical Officer and New Members of Scientific and Strategic Advisory Board - Global immuno-oncology experts bring decades of experience to advance company?s transformative research and development pipeline - SAN FRANCISCO, Calif. and SUZHOU, China, August 12, 2021 ? Adagene Inc. (?Adagene? or the ?Company?) (Nasdaq: ADAG), a platform-driv |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2021 Commission File Number: 001-39997 Adagene Inc. (Exact Name of Registrant as Specified in Its Charter) 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu |
|
| July 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2021 Commission File Number: 001-39997 Adagene Inc. (Exact Name of Registrant as Specified in Its Charter) 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu P |
|
| July 22, 2021 |
EX-99.1 2 tm2122076d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Adagene Announces Clinical Trial Collaboration With Merck to Advance Two Anti-CTLA-4 Monoclonal Antibody Programs (ADG116 and ADG126) in Combination Therapy with KEYTRUDA® (pembrolizumab) - Two global clinical studies to evaluate NEObody™ product candidate, ADG116, and SAFEbody™ product candidate, ADG126, in combination with KEYTRUDA® (pemb |
|
| July 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2021 Commission File Number: 001-39997 Adagene Inc. (Exact Name of Registrant as Specified in Its Charter) 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu P |
|
| July 7, 2021 |
Adagene Announces Authorization of Share Repurchase Program up to US$20 Million Exhibit 99.1 Adagene Announces Authorization of Share Repurchase Program up to US$20 Million SAN FRANCISCO, Calif. and SUZHOU, China, July 7, 2021 ? Adagene Inc. (?Adagene?) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced that its board of directors has autho |
|
| May 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2021 Commission File Number: 001-39997 Adagene Inc. (Exact Name of Registrant as Specified in Its Charter) 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu Pr |
|
| May 19, 2021 |
EX-99.1 2 tm2116938d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Adagene Presents Clinical Data from NEObodyTM Program, ADG106, Anti-CD137 Agonist, in an Abstract at ASCO 2021 Annual Meeting -Identified a predictive biomarker and two pharmacodynamic biomarkers that correlate with clinical efficacy and target engagement -ADG106, a fully human, ligand-blocking, agonistic anti-CD137 antibody demonstrated a |
|
| April 28, 2021 |
Consent of Walkers (Hong Kong) Exhibit 15.2 Partners: Paul Aherne ** Joanne Collett * Mark Cummings ***** Stuart D’Addona **** Nicholas Davies *** Shamar Ennis *** James Gaden **** Kristen Kwok ** Jo Lit * Callum McNeil ** Alice Molan ****** Andrew Randall ** Rupen Shah ******* Denise Wong ** 28 April 2021 Adagene Inc. 4F, Building C14, No.218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu Province, 215123 People’s Repub |
|
| April 28, 2021 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Adagene Inc. (the ?Company?) on Form 20-F for the year ended December 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the ?Report?), I, Peter (Peizhi) Luo, Chief Executive Officer, certify, pursuant to |
|
| April 28, 2021 |
Exhibit 15.1 10/F, Tower B, CPIC Plaza, No. 28 Fengsheng Lane, Xicheng District, Beijing 100032, China Tel: 86 10 5776 3888 Fax: 86 10 5776 3777 April 28, 2021 To: Adagene Inc. 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu Province, People’s Republic of China (as the “Company”) Dear Sirs, We consent to the references to our firm under the headings “Item 10. Additi |
|
| April 28, 2021 |
Description of Registrant’s Securities Exhibit 2.5 Description of Rights of Each Class of Securities Registered under Section 12 of the Securities Exchange Act of 1934 (the ?Exchange Act?) American Depositary Shares (?ADSs?), each representing one and one quarter ordinary shares of Adagene Inc. (?our company? or ?us?) are listed on the Nasdaq Global Market and the shares are registered under Section 12(b) of the Exchange Act. This exhi |
|
| April 28, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(B) OR 12(G) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020. OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) |
|
| April 28, 2021 |
Exhibit 12.1 CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Peter (Peizhi) Luo, certify that: 1. I have reviewed this annual report on Form 20-F of Adagene Inc. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statement |
|
| April 28, 2021 |
Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Adagene Inc. (the “Company”) on Form 20-F for the year ended December 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Man Kin (Raymond) Tam, Chief Financial Officer, certify, pursuant |
|
| April 28, 2021 |
Consent of PricewaterhouseCoopers Zhong Tian LLP, Independent Registered Public Accounting Firm Exhibit 15.3 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (File No. 333-255250) of Adagene Inc. of our report dated April 28, 2021 relating to the financial statements, which appears in this Form 20-F. /s/PricewaterhouseCoopers Zhong Tian LLP Shanghai, the People?s Republic of China April 28, |
|
| April 28, 2021 |
Exhibit 12.2 CERTIFICATION BY PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Man Kin (Raymond) Tam, certify that: 1. I have reviewed this annual report on Form 20-F of Adagene Inc. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements |
|
| April 15, 2021 |
As filed with the Securities and Exchange Commission on April 15, 2021 Registration No. |
|
| April 13, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2021 Commission File Number: 001-39997 Adagene Inc. (Exact Name of Registrant as Specified in Its Charter) 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu |
|
| April 13, 2021 |
EX-99.1 2 a21-128381ex99d1.htm EX-99.1 Exhibit 99.1 Adagene Presents Preclinical Data from Lead SAFEbodyTM Program, ADG126, at the American Association for Cancer Research (AACR) Annual Meeting 2021 SAN FRANCISCO, Calif. and SUZHOU, China, April 13, 2021 — Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery an |
|
| March 31, 2021 |
Exhibit 99.1 Adagene Reports Full Year 2020 Financial Results and Provides Corporate Updates - Successfully completed Initial Public Offering raising approximately US$161 million in gross proceeds- -Reported clinical data for anti-CD137 and two anti-CTLA-4 programs- -Advanced five discovery programs into IND-enabling stage- -Established multiple academic and industry partnerships- -Further strengt |
|
| March 31, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2021 Commission File Number: 001-39997 Adagene Inc. (Exact Name of Registrant as Specified in Its Charter) 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu |
|
| March 29, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2021 Commission File Number: 001-39997 Adagene Inc. (Exact Name of Registrant as Specified in Its Charter) 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu |
|
| March 29, 2021 |
EX-99.1 2 a21-111751ex99d1.htm EX-99.1 Exhibit 99.1 Adagene Announces Clinical Advancement for ADG116 -NEObody™ product candidate ADG116 has been well tolerated in ongoing Phase 1 clinical trial- - Promising pharmacodynamic biomarker signals demonstrate clinical proof of mechanism- -Poised for global expansion- SAN FRANCISCO, Calif. and SUZHOU, China, March 29, 2021 — Adagene Inc. (Nasdaq: ADAG), |
|
| March 16, 2021 |
EX-99.1 2 a21-98661ex99d1.htm EX-99.1 Exhibit 99.1 Adagene Announces First Patients Dosed in Global Phase 1 Clinical Trial of ADG126, Lead SAFEbody™ Program -SAFEbody technology enables precision masking of antibodies for enhanced safety- SAN FRANCISCO, Calif. and SUZHOU, China, March 16, 2021 — Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company co |
|
| March 16, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2021 Commission File Number: 001-39997 Adagene Inc. (Exact Name of Registrant as Specified in Its Charter) 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu |
|
| February 10, 2021 |
7,354,000 American Depositary Shares Adagene Inc. Representing 9,192,500 Ordinary Shares Use these links to rapidly review the document TABLE OF CONTENTS INDEX TO THE CONSOLIDATED FINANCIAL STATEMENTS Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. |
|
| February 5, 2021 |
QuickLinks - Click here to rapidly navigate through this document As filed with the Securities and Exchange Commission on February 5, 2021 Registration No. |
|
| February 5, 2021 |
Form of Underwriting Agreement Exhibit 1.1 ADAGENE INC. ORDINARY SHARES, PAR VALUE US$0.0001 PER SHARE in the Form of American Depositary Shares UNDERWRITING AGREEMENT [·], 2021 GOLDMAN SACHS (ASIA) L.L.C. MORGAN STANLEY & CO. LLC JEFFERIES LLC As Representatives of the several Underwriters named in Schedule A hereto c/o Goldman Sachs (Asia) L.L.C. 68th Floor, Cheung Kong Center 2 Queen’s Road Central Hong Kong c/o Morgan Stanl |
|
| February 4, 2021 |
Goldman Sachs (Asia) L.L.C. 68th Floor, Cheung Kong Center 2 Queen?s Road Central Hong Kong Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 U.S.A. Jefferies LLC 520 Madison Avenue New York, New York 10022 U.S.A. As representatives of the prospective underwriters VIA EDGAR February 4, 2021 Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commissio |
|
| February 4, 2021 |
New York Northern California Washington DC S?o Paulo London Paris Madrid Hong Kong Beijing Tokyo Resident Hong Kong Partners Davis Polk & Wardwell Hong Kong Solicitors The Hong Kong Club Building 3A Chater Road Hong Kong 852 2533 3300 tel Karen Chan ? Martin Rogers ? Yang Chu ? Patrick S. |
|
| February 4, 2021 |
February 4, 2021 VIA EDGAR Mr. Jason Drory Ms. Celeste Murphy Ms. Tracey Houser Mr. Terence O?Brien Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Re: Adagene Inc. (CIK No. 0001818838) Registration Statement on Form F-1 (File No. 333-252210) Registration Statement on Form 8-A (File No. 001-39997) Ladies and Ge |
|
| February 3, 2021 |
New York Northern California Washington DC S?o Paulo London Paris Madrid Hong Kong Beijing Tokyo Resident Hong Kong Partners Davis Polk & Wardwell Hong Kong Solicitors The Hong Kong Club Building 3A Chater Road Hong Kong 852 2533 3300 tel Karen Chan ? Yang Chu ? James C. |
|
| February 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Adagene Inc. (Exact name of Registrant as specified in Its charter) Cayman Islands Not Applicable (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) |
|
| February 3, 2021 |
Use these links to rapidly review the document TABLE OF CONTENTS INDEX TO THE CONSOLIDATED FINANCIAL STATEMENTS Table of Contents As filed with the Securities and Exchange Commission on February 3, 2021 Registration No. |
|
| February 1, 2021 |
New York Paris Northern California Madrid Washington DC Hong Kong S?o Paulo Beijing London Tokyo Resident Hong Kong Partners Davis Polk & Wardwell 852 2533 3300 tel Karen Chan ? Martin Rogers ? Hong Kong Solicitors Yang Chu ? Patrick S. |
|
| February 1, 2021 |
Exhibit 10.14 Confidential Execution Version *** CERTAIN MATERIAL (INDICATED BY THREE ASTERISKS IN BRACKETS) HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH (1) NOT MATERIAL AND (2) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. COLLABORATION AND LICENSE AGREEMENT THIS COLLABORATION AND LICENSE AGREEMENT (the “Agreement”) is entered into as of February 1, 2021 (the “Effective Date”), |
|
| February 1, 2021 |
New York Northern California Washington DC S?o Paulo London Paris Madrid Hong Kong Beijing Tokyo Resident Hong Kong Partners Davis Polk & Wardwell Hong Kong Solicitors The Hong Kong Club Building 3A Chater Road Hong Kong 852 2533 3300 tel Karen Chan ? Yang Chu ? James C. |
|
| February 1, 2021 |
New York Northern California Washington DC S?o Paulo London Paris Madrid Hong Kong Beijing Tokyo Resident Hong Kong Partners Davis Polk & Wardwell Hong Kong Solicitors The Hong Kong Club Building 3A Chater Road Hong Kong 852 2533 3300 tel Karen Chan ? Yang Chu ? James C. |
|
| February 1, 2021 |
Use these links to rapidly review the document TABLE OF CONTENTS INDEX TO THE CONSOLIDATED FINANCIAL STATEMENTS Table of Contents As filed with the Securities and Exchange Commission on February 1, 2021 Registration No. |
|
| February 1, 2021 |
Exhibit 3.2 THE COMPANIES ACT (AS AMENDED) OF THE CAYMAN ISLANDS COMPANY LIMITED BY SHARES SEVENTH AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION OF ADAGENE INC. (ADOPTED BY SPECIAL RESOLUTION PASSED ON JANUARY 19, 2021 AND EFFECTIVE CONDITIONAL AND IMMEDIATELY PRIOR TO THE COMPLETION OF THE COMPANY’S INITIAL PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES REPRESENTING ITS ORDINARY SHAR |
|
| February 1, 2021 |
New York Northern California Washington DC S?o Paulo London Paris Madrid Hong Kong Beijing Tokyo Resident Hong Kong Partners Davis Polk & Wardwell Hong Kong Solicitors The Hong Kong Club Building 3A Chater Road Hong Kong 852 2533 3300 tel Karen Chan ? Yang Chu ? James C. |
|
| January 29, 2021 |
- REGISTRATION STATEMENT FOR AMERICAN DEPOSITARY RECEIPTS As filed with the U.S. Securities and Exchange Commission on January 29, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-6 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 For Depositary Shares Evidenced by American Depositary Receipts Adagene Inc. (Exact name of issuer of deposited securities as specified in its charter) N/A (Transl |
|
| January 29, 2021 |
Adagene Inc. F-6 Exhibit (a) Execution TABLE OF CONTENTS Page PARTIES 1 RECITALS 1 Section 1. Certain Definitions (a) ADR Register 1 (b) ADRs; Direct Registration ADRs 1 (c) ADS 1 (d) Beneficial Owner 1 (e) Custodian 2 (f) Deliver, execute, issue et al. 2 (g) Delivery Order 2 (h) Deposited Securities 2 (i) Direct Registration System 2 (j) Holder 2 (k) Securities Act of 1933 2 (l) Securities Exchan |
|
| January 29, 2021 |
EX-99.(D) 3 ex99-d.htm OPINION OF TROUTMAN PEPPER HAMILTON SANDERS LLP Adagene Inc. F-6 Exhibit (d) Troutman Pepper Hamilton Sanders LLP 875 Third Avenue New York, NY 10022 troutman.com 212.704.6000 Fax 212.704.6288 January 29, 2021 JPMorgan Chase Bank, N.A., as Depositary 383 Madison Avenue, Floor 11 New York, NY 10179 Re: Registration Statement on Form F-6 – American Depositary Shares evidenced |
|
| January 19, 2021 |
EX-10.6 15 a2242683zex-106.htm EX-10.6 Exhibit 10.6 Execution Version SHARE PURCHASE AGREEMENT THIS SHARE PURCHASE AGREEMENT (this “Agreement”) is made and entered into on February 2, 2018 by and among: 1. Adagene Inc., an exempted company organized under the laws of the Cayman Islands (the “Company”); 2. Adagene (Hong Kong) Limited (天演藥業(香港)有限公司), a company organized under the laws of Hong Kong ( |
|
| January 19, 2021 |
Exhibit 10.10 *** CERTAIN MATERIAL (INDICATED BY THREE ASTERISKS IN BRACKETS) HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH (1) NOT MATERIAL AND (2) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Dragon Boat Biopharmaceutical (Shanghai) Limited. AND Adagene Inc. Cooperation Agreement on International Interests of [***] Project May 2019 1 CONTENTS ARTICLE 1 PURPOSE AND CONTENT OF CO |
|
| January 19, 2021 |
EX-10.5 14 a2242683zex-105.htm EX-10.5 Exhibit 10.5 Execution Version SHARE PURCHASE AGREEMENT THIS SHARE PURCHASE AGREEMENT (this “Agreement”) is made and entered into on June 9, 2019 by and among: 1. Adagene Inc., an exempted company organized under the laws of the Cayman Islands (the “Company”); 2. Adagene (Hong Kong) Limited (天演藥業(香港)有限公司), a company organized under the laws of Hong Kong (the |
|
| January 19, 2021 |
EX-10.7 16 a2242683zex-107.htm EX-10.7 Exhibit 10.7 *** CERTAIN MATERIAL (INDICATED BY THREE ASTERISKS IN BRACKETS) HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH (1) NOT MATERIAL AND (2) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Guilin Sanjin Pharmaceutical Co., Ltd. AND Adagene (Suzhou) Limited Cooperation Agreement on the PD-L1 Project December 2018 1 CONTENTS ARTICLE 1 PURP |
|
| January 19, 2021 |
EX-3.1 2 a2242683zex-31.htm EX-3.1 Exhibit 3.1 THE COMPANIES LAW (REVISED) OF THE CAYMAN ISLANDS COMPANY LIMITED BY SHARES SIXTH AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION OF ADAGENE INC. (adopted by a special resolution passed on December 19, 2019) THE COMPANIES LAW (REVISED) OF THE CAYMAN ISLANDS COMPANY LIMITED BY SHARES SIXTH AMENDED AND RESTATED MEMORANDUM OF ASSOCIATION OF A |
|
| January 19, 2021 |
Consent of Man Kin (Raymond) Tam Exhibit 99.6 January 19, 2021 Adagene Inc. (the “Company”) 4F, Building C14, No. 218, Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu Province, 25125 People’s Republic of China Ladies and Gentlemen: Pursuant to Rule 438 under the Securities Act of 1933, as amended, I hereby consent to the reference of my name as a director of the Company, effective immediately upon the effectiveness of the C |
|
| January 19, 2021 |
Consent of Andy (Yiu Leung) Cheung Exhibit 99.4 January 19, 2021 Adagene Inc. (the “Company”) 4F, Building C14, No. 218, Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu Province, 25125 People’s Republic of China Ladies and Gentlemen: Pursuant to Rule 438 under the Securities Act of 1933, as amended, I hereby consent to the reference of my name as a director of the Company, effective immediately upon the effectiveness of the C |
|
| January 19, 2021 |
Exhibit 10.9 *** CERTAIN MATERIAL (INDICATED BY THREE ASTERISKS IN BRACKETS) HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH (1) NOT MATERIAL AND (2) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Dragon Boat Biopharmaceutical (Shanghai) Limited. AND Adagene (Suzhou) Limited Cooperation Agreement on the [***] Project May 2019 1 CONTENTS ARTICLE 1 PURPOSE AND CONTENT OF THE COOPERATIO |
|
| January 19, 2021 |
Adagene Inc. 2021 Performance Incentive Plan EX-10.13 22 a2242683zex-1013.htm EX-10.13 Exhibit 10.13 ADAGENE INC. 2021 PERFORMANCE INCENTIVE PLAN 1. PURPOSE OF PLAN The purpose of this Adagene Inc. 2021 Performance Incentive Plan (this “Plan”) of Adagene Inc., an exempted company organized under the Companies Law, Cap 22 (Law 3 of 1961, as consolidated and revised) of the Cayman Islands (the “Company”), is to promote the success of the Compa |
|
| January 19, 2021 |
Exhibit 10.11 *** CERTAIN MATERIAL (INDICATED BY THREE ASTERISKS IN BRACKETS) HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH (1) NOT MATERIAL AND (2) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. CONFIDENTIAL MATERIAL TRANSFER AND COLLABORATION AGREEMENT This Material Transfer and Option Agreement (“Agreement”), is made on April 11, 2019 (“Effective Date”) and is entered into by an |
|
| January 19, 2021 |
Adagene Inc. Second Amended and Restated Share Incentive Plan Exhibit 10.1 ADAGENE INC. SECOND AMENDED AND RESTATED SHARE INCENTIVE PLAN PREFACE This Plan is divided into two separate equity programs: (1) the option and share appreciation rights grant program set forth in Section 5 under which Eligible Persons (as defined in Section 3) may, at the discretion of the Administrator, be granted Options and/or SARs, and (2) the share award program set forth in Se |
|
| January 19, 2021 |
License Agreement Among ADC Therapeutics SA and Adagene Inc. dated April 11, 2019 Exhibit 10.12 *** CERTAIN MATERIAL (INDICATED BY THREE ASTERISKS IN BRACKETS) HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH (1) NOT MATERIAL AND (2) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. CONFIDENTIAL LICENSE AGREEMENT AMONG ADC THERAPEUTICS SA AND ADAGENE Inc. LICENSE AGREEMENT THIS LICENSE AGREEMENT (“License Agreement”) is made and entered into as of April 11, 2019 (“Exe |
|
| January 19, 2021 |
Exhibit 4.5 FOURTH AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT BY AND BETWEEN ADAGENE INC. NON-INVESTOR SHAREHOLDERS AND INVESTORS NAMED HEREIN DECEMBER 19, 2019 Table of Contents 1. Definitions 2 1.1 Definitions 2 1.2 Other Defined Terms 7 1.3 Interpretation 7 2. Restriction on Transfers; Rights of First Refusal and Co-Sale Rights 8 2.1 Restriction on Transfers 8 2.2 Rights |
|
| January 19, 2021 |
Exhibit 3.2 THE COMPANIES ACT (AS AMENDED) OF THE CAYMAN ISLANDS COMPANY LIMITED BY SHARES SEVENTH AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION OF ADAGENE INC. (ADOPTED BY SPECIAL RESOLUTION PASSED ON JANUARY 19, 2021 AND EFFECTIVE CONDITIONAL AND IMMEDIATELY PRIOR TO THE COMPLETION OF THE COMPANY’S INITIAL PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES REPRESENTING ITS ORDINARY SHAR |
|
| January 19, 2021 |
EX-10.4 13 a2242683zex-104.htm EX-10.4 Exhibit 10.4 Execution Version SHARE PURCHASE AGREEMENT THIS SHARE PURCHASE AGREEMENT (this “Agreement”) is made and entered into on October 15, 2019 by and among: 1. Adagene Inc., an exempted company organized under the laws of the Cayman Islands (the “Company”); 2. Adagene (Hong Kong) Limited (天演藥業(香港)有限公司), a company organized under the laws of Hong Kong ( |
|
| January 19, 2021 |
Form of Employment Agreement between the Registrant and an executive officer of the Registrant Exhibit 10.3 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into, by and between Adagene Inc., a company incorporated and existing under the laws of the Cayman Islands (the “Company” and, together with all of its direct or indirect parent companies, subsidiaries, affiliates, or subsidiaries or affiliates of its parent companies, collectively referred to as th |
|
| January 19, 2021 |
Opinion of Davis Polk & Wardwell LLP regarding material U.S. federal income tax consequences Exhibit 8.3 New York Paris Northern California Madrid Washington DC Hong Kong São Paulo Beijing London Tokyo Davis Polk & Wardwell LLP 212 450 4000 tel 450 Lexington Avenue 212 701 5800 fax New York, NY 10017 January 19, 2021 Re: Registration Statement on Form F-1 Adagene Inc. 4F, Building C14, No. 218, Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu Province, 25125 People’s Republic of Chin |
|
| January 19, 2021 |
Code of Business Conduct and Ethics of the Registrant EX-99.1 25 a2242683zex-991.htm EX-99.1 Exhibit 99.1 Adagene Inc. (the “Company”) Code of Business Conduct and Ethics Adopted January 16, 2021 Introduction This Code of Business Conduct and Ethics (the “Code”) has been adopted by our Board of Directors (the “Board”) and summarizes the standards that must guide our actions. Although they cover a wide range of business practices and procedures, these |
|
| January 19, 2021 |
Opinion of Tian Yuan Law Firm regarding certain PRC tax matters (included in Exhibit 99.2) Exhibit 99.2 January 19, 2021 To: Adagene Inc. 4F, Building C14, No. 218, Xinghu Street, Suzhou Industrial Park, Suzhou, Jiangsu Province, People’s Republic of China Re: Legal Opinion Regarding Certain PRC Law Matters We are qualified lawyers of the People’s Republic of China (the “PRC”) and are qualified to issue an opinion on the laws and regulations of the PRC (for the purposes of this opinion, |
|
| January 19, 2021 |
Exhibit 4.3 TABLE OF CONTENTS Page PARTIES 1 RECITALS 1 Section 1. Certain Definitions (a) ADR Register 1 (b) ADRs; Direct Registration ADRs 1 (c) ADS 1 (d) Beneficial Owner 1 (e) Custodian 2 (f) Deliver, execute, issue et al. 2 (g) Delivery Order 2 (h) Deposited Securities 2 (i) Direct Registration System 2 (j) Holder 2 (k) Securities Act of 1933 2 (l) Securities Exchange Act of 1934 3 (m) Shares |
|
| January 19, 2021 |
EX-4.2 4 a2242683zex-42.htm EX-4.2 Exhibit 4.2 Adagene Inc. INCORPORATED IN THE CAYMAN ISLANDS UNDER THE COMPANIES LAW (AS AMENDED OR REVISED FROM TIME TO TIME) Certificate Number Number of Shares THE AUTHORISED CAPITAL OF THE COMPANY IS USD 80,000.00 DIVIDED INTO 800,000,000 ORDINARY SHARES OF PAR VALUE USD 0.0001 EACH THIS CERTIFIES THAT OF IS THE OWNER OF fully paid Ordinary shares of par value |
|
| January 19, 2021 |
EX-10.2 11 a2242683zex-102.htm EX-10.2 Exhibit 10.2 FORM OF INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of , 20 between (i) Adagene Inc., an exempted company organized under the laws of the Cayman Islands (the “Company”) and (ii) , an individual holding a numbered serving as [ of the Company (the “Officer”)]/[a director of the Company (the |
|
| January 19, 2021 |
Exhibit 10.8 *** CERTAIN MATERIAL (INDICATED BY THREE ASTERISKS IN BRACKETS) HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH (1) NOT MATERIAL AND (2) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Guilin Sanjin Pharmaceutical Co., Ltd. AND Adagene Inc. Cooperation Agreement on International Interests of PD-L1 Project December 2018 1 CONTENTS ARTICLE 1 PURPOSE AND CONTENT OF COOPERATI |
|
| January 19, 2021 |
Exhibit 99.3 January 19, 2021 Adagene Inc. 4F, Building C14, No. 218, Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu Province, 25125 People’s Republic of China Re: Consent of Frost & Sullivan Ladies and Gentlemen, Reference is made to the registration statement on Form F-1 (the “Registration Statement”) filed by Adagene Inc. (the “Company”) with the United States Securities and Exchange Com |
|
| January 19, 2021 |
Exhibit 99.5 January 19, 2021 Adagene Inc. (the “Company”) 4F, Building C14, No. 218, Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu Province, 25125 People’s Republic of China Ladies and Gentlemen: Pursuant to Rule 438 under the Securities Act of 1933, as amended, I hereby consent to the reference of my name as a director of the Company, effective immediately upon the effectiveness of the C |
|
| January 19, 2021 |
Use these links to rapidly review the document TABLE OF CONTENTS INDEX TO THE CONSOLIDATED FINANCIAL STATEMENTS Table of Contents As filed with the Securities and Exchange Commission on January 19, 2021 Registration No. |
